Int J Cardiol:Takotsubo综合征中不良院内结局的心电图预测因子

2019-06-23 xing.T MedSci原创

由此可见,T波倒置在TS中很常见,并且由于VT/VF风险较低而导致MACE风险降低。

Takotsubo综合征(TS)是一种威胁生命的急性心力衰竭综合征。然而,对于TS中较差结果的危险因素知之甚少,并且没有定义高风险ECG标准。近日,心血管领域权威杂志International Journal of Cardiology上发表了一篇研究文章,研究人员试图确定TS中危及生命的院内并发症的心电图预测因子。 

研究人员使用全国范围的瑞典血管造影和血管成形术登记中心(SCAAR)获得了2008年6月至2019年2月期间在Sahlgrenska大学医院接受冠状动脉造影的所有连续患者的数据。对于所有TS患者,研究人员进行了深入的图表检查以确认TS诊断。对于已确诊TS的患者,研究人员随后评估了住院期间获得的所有ECG。主要终点是住院期间主要心脏不良事件(MACE)的发生,定义为死亡、室性心动过速或纤颤(VT/VF),或房室传导阻滞≥2或心搏停止>10s的复合事件。

研究人员确定了215例TS患者(平均年龄69±13岁; 93%为女性)。MACE发生于34例患者(16%),其中20例患有VT/VF(9.3%)。没有临床变量与MACE显著相关。MACE患者比没有MACE的患者更不可能有窦性心律(85% vs. 96%,p=0.025)或T波倒置(29% vs. 51%,p=0.025)。倾向评分调整后,T波倒置与较低的MACE风险(调整后的比值比[AdjOR]为0.28,95%置信区间[CI]为0.10-0.76,p=0.012)和VT/VF(AdjOR为0.24,95%CI为0.06-0.94,p=0.041)独立相关。 

由此可见,T波倒置在TS中很常见,并且由于VT/VF风险较低而导致MACE风险降低。 

原始出处:

SandeepJha,et al.Electrocardiographic predictors of adverse in-hospital outcomes in the Takotsubo syndrome.International Journal of Cardiology.2019.https://doi.org/10.1016/j.ijcard.2019.06.021

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1782043, encodeId=80b41e820437c, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Nov 29 16:11:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310731, encodeId=38e51310e3110, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Tue Jun 25 00:11:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431555, encodeId=0c71143155544, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 25 00:11:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590582, encodeId=85a215905827f, content=<a href='/topic/show?id=53691e108c5' target=_blank style='color:#2F92EE;'>#Takotsubo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17108, encryptionId=53691e108c5, topicName=Takotsubo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04c017833400, createdName=axin015, createdTime=Tue Jun 25 00:11:00 CST 2019, time=2019-06-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1782043, encodeId=80b41e820437c, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Nov 29 16:11:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310731, encodeId=38e51310e3110, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Tue Jun 25 00:11:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431555, encodeId=0c71143155544, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 25 00:11:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590582, encodeId=85a215905827f, content=<a href='/topic/show?id=53691e108c5' target=_blank style='color:#2F92EE;'>#Takotsubo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17108, encryptionId=53691e108c5, topicName=Takotsubo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04c017833400, createdName=axin015, createdTime=Tue Jun 25 00:11:00 CST 2019, time=2019-06-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1782043, encodeId=80b41e820437c, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Nov 29 16:11:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310731, encodeId=38e51310e3110, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Tue Jun 25 00:11:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431555, encodeId=0c71143155544, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 25 00:11:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590582, encodeId=85a215905827f, content=<a href='/topic/show?id=53691e108c5' target=_blank style='color:#2F92EE;'>#Takotsubo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17108, encryptionId=53691e108c5, topicName=Takotsubo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04c017833400, createdName=axin015, createdTime=Tue Jun 25 00:11:00 CST 2019, time=2019-06-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1782043, encodeId=80b41e820437c, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Nov 29 16:11:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310731, encodeId=38e51310e3110, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Tue Jun 25 00:11:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431555, encodeId=0c71143155544, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 25 00:11:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590582, encodeId=85a215905827f, content=<a href='/topic/show?id=53691e108c5' target=_blank style='color:#2F92EE;'>#Takotsubo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17108, encryptionId=53691e108c5, topicName=Takotsubo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04c017833400, createdName=axin015, createdTime=Tue Jun 25 00:11:00 CST 2019, time=2019-06-25, status=1, ipAttribution=)]
    2019-06-25 axin015

相关资讯

JACC:Takotsubo综合征发病机制的研究

Takotsubo综合征(TTS)是一种急性左室功能不全,并且急性期可能会致命的临床综合征。目前,TTS的发病机制尚未阐明。近日,在国际心血管权威杂志JACC上发表了一篇旨在建立TTS体外引导性多能干细胞(IPSC)模型以研究儿茶酚胺-β信号通路是否在IPSC-心肌细胞(CMs)有所改变,并探究其机制的研究。本研究将TTS患者和正常对照的体细胞提取,诱导为IPSC,并分化为心肌细胞。三个月大的心肌

JAHA:复发性Takotsubo综合征的发病率和临床影响

由此可见,在这个多中心TTS登记中心,TTS复发的发生率估计为4%。复发的可变TTS模式在复发病例中很常见,可高达20%。

Int J Cardiol:Takotsubo综合征患者的入院心率与住院病程

由此可见,在患有TS的大型人群中,入院时较高的HR可独立预测复杂的住院病程。

JACC:Takotsubo综合征的远期预后研究

目前,由于临床资料的局限性,关于Takotsubo综合征(TTS)的远期预后尚不清楚。本研究的目的旨在比较和评估TTS和急性冠脉综合征(ACS)患者的预后,并基于不同的触发因素评估TTS的短期和长期预后情况。本研究纳入了1613名TTS患者,并将其与年龄和性别相匹配的ACS患者进行预后情况的比较。在1613名TTS患者中,有485名(30%)患者的触发因素为情感因素,630名(39%)患者的触发因

Diabetes Care:Takotsubo综合征患者糖尿病的患病率和预后影响!

由此可见,TTS患者中糖尿病并不常见,它与长期死亡率增加有关,并且与其他危险因素无关,是预后不良的独立预测因子。